Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kiromic Biopharma Inc (OP: KRBP )

1.090 -0.040 (-3.54%)
Streaming Delayed Price Updated: 2:46 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 865
Open 0.9100
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.130
Today's Range 0.9100 - 1.090
52wk Range 0.1800 - 3.780
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire

Performance

YTD
+17.84%
+17.84%
1 Month
+19.78%
+19.78%
3 Month
-46.31%
-46.31%
6 Month
-66.15%
-66.15%
1 Year
+263.33%
+263.33%

More News

Read More
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
From Kiromic BioPharma, Inc.
Via Business Wire
KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024
Via InvestorPlace
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.